Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Welcome2: Certolizumab pegol long-term extension in Crohn's disease
NCT00333788Phase 3Completed
- Sponsor
- UCB
- Start
- Oct 2006
- Primary completion
- Apr 2010
- Modality
- Antibody Fragments, Polymer-based Nanoparticles
- Countries
- 12
01
Overview
Phase 3, open-label, single-arm trial of certolizumab pegol in Crohn's disease, sponsored by UCB. Primary endpoint: Occurrence of at Least One Study-emergent Adverse Event During the Study at 164 weeks. Started Oct 2006; status: completed.
02
Drugs
certolizumab pegol
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on NCT00333788.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00333788.